Archive · 23 Jul 2025
Cipla Balances Legacy and Innovation in a Changing Market
Imagine a company that's been around for a really long time, like a grandparent.
That's Cipla, a big medicine maker in India.
They're trying to become cooler and more modern, like a new brand.
They make lots of medicines, including one for breathing problems that's very popular.
They're also selling things like medicine for coughs and colds, but not many people know they're from Cipla.
The company wants to be more than just a medicine maker, and they're exploring new things like tests and tools to help people stay healthy.
It's like they're trying to catch up with the times, as they look to the future.
Cipla, a 90-year-old pharmaceutical company, aims to modernize its brand image.
The company reported a revenue of Rs 19,044.85 crore in FY25, up from the previous year.
Foracort, Cipla's respiratory product, became the top-selling pharma brand in India in 2023.
Cipla is expanding into OTC and wellness products but faces challenges in brand recognition.
The company is exploring new markets and expanding into the 'continuum of care', including diagnostics.
- Who
- Cipla, a pharmaceutical company.
- What
- Cipla, a 90-year-old pharmaceutical company, is working to modernize its brand and expand its offerings.
- When
- FY25.
- Where
- India, with expansions planned in other markets like the U.S. and Europe.
- Why
- Cipla aims to adapt to a rapidly changing market, increase brand recognition, and expand its offerings beyond just medicines.
Legacy vs. Innovation
Brand Visibility vs. Product Focus
Balancing Act
Legacy vs. Innovation
Maintain brand trust with the company’s legacy
Brand Visibility vs. Product Focus
Adapt and innovate to stay relevant in a dynamic market
- Company Age
- 90 years
- FY25 Revenue
- Rs 19,044.85 crore
- FY24 Revenue
- Rs 16,574.34 crore
- FY25 Profit
- Rs 6,189.27 crore
- Main Product
- Foracort (respiratory)
- OTC Market Rank
- 2nd largest